MX381475B - Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer. - Google Patents

Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer.

Info

Publication number
MX381475B
MX381475B MX2018001659A MX2018001659A MX381475B MX 381475 B MX381475 B MX 381475B MX 2018001659 A MX2018001659 A MX 2018001659A MX 2018001659 A MX2018001659 A MX 2018001659A MX 381475 B MX381475 B MX 381475B
Authority
MX
Mexico
Prior art keywords
inhibitor
topoisomerase
tumor
cancer
parp
Prior art date
Application number
MX2018001659A
Other languages
English (en)
Other versions
MX2018001659A (es
Inventor
Daryl C Drummond
Jonathan Basil Fitzgerald
Sarah F Blanchette
Victor Moyo
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56801880&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX381475(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Publication of MX2018001659A publication Critical patent/MX2018001659A/es
Publication of MX381475B publication Critical patent/MX381475B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan terapias de combinación para tratar el cáncer, que comprenden la administración de un inhibidor de la topoisomerasa 1 y un inhibidor de PARP. El inhibidor de la topoisomerasa 1 puede administrarse como una formulación liposomal que proporciona una acumulación prolongada del inhibidor de la topoisomerasa 1 dentro de un tumor en relación con el exterior del tumor. De esta manera puede obtenerse un beneficio terapéutico mediante el retraso de la administración del inhibidor de PARP después de cada administración de una formulación de irinotecán liposomal hasta que la acumulación del inhibidor de la topoisomerasa en el tumor sea suficientemente mayor que fuera del tumor para dar lugar a una mayor eficacia del inhibidor de PARP y del inhibidor de la topoisomerasa dentro del tumor, al tiempo que se reduce la toxicidad periférica de la terapia de combinación. Las terapias que se describen en esta descripción son útiles en el tratamiento de cánceres humanos con tumores sólidos, que incluyen el cáncer de cuello uterino. Por ejemplo, los métodos para tratar a un paciente que tiene cáncer, con una combinación de un inhibidor de Topi liposomal, p. ej., MM-398, y veliparib.
MX2018001659A 2015-08-20 2016-08-19 Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer. MX381475B (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562207760P 2015-08-20 2015-08-20
US201562207709P 2015-08-20 2015-08-20
US201562269756P 2015-12-18 2015-12-18
US201562269511P 2015-12-18 2015-12-18
US201662308924P 2016-03-16 2016-03-16
US201662323422P 2016-04-15 2016-04-15
PCT/US2016/047814 WO2017031442A1 (en) 2015-08-20 2016-08-19 Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment

Publications (2)

Publication Number Publication Date
MX2018001659A MX2018001659A (es) 2018-05-28
MX381475B true MX381475B (es) 2025-03-12

Family

ID=56801880

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001659A MX381475B (es) 2015-08-20 2016-08-19 Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer.

Country Status (18)

Country Link
US (4) US9895365B2 (es)
EP (1) EP3337467B1 (es)
JP (1) JP7042739B2 (es)
KR (1) KR20180037210A (es)
CN (1) CN108348480A (es)
AU (1) AU2016309002B2 (es)
CA (1) CA2992789A1 (es)
ES (1) ES2848118T3 (es)
HK (1) HK1257216A1 (es)
IL (1) IL257147B (es)
MX (1) MX381475B (es)
PL (1) PL3337467T3 (es)
PT (1) PT3337467T (es)
RU (1) RU2760185C2 (es)
SG (1) SG10201913073YA (es)
SI (1) SI3337467T1 (es)
TW (1) TWI724018B (es)
WO (2) WO2017031445A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA86063C2 (ru) 2004-05-03 2009-03-25 Хермес Біосайенсез, Інк. Липосомы для снабжения лекарств
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
JP7113619B2 (ja) * 2014-12-09 2022-08-05 イプセン バイオファーム リミティド リポソーマルイリノテカンによる乳がんの治療
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
PL3337467T3 (pl) 2015-08-20 2021-06-14 Ipsen Biopharm Ltd. Terapia skojarzona z zastosowaniem liposomalnego irynotekanu i inhibitora parp do leczenia nowotworu
IL257149B2 (en) 2015-08-21 2024-11-01 Ipsen Biopharm Ltd Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
MX382522B (es) 2015-10-16 2025-03-13 Ipsen Biopharm Ltd Composiciones farmaceuticas estabilizantes de camptotecina.
EP3535026A1 (en) 2016-11-02 2019-09-11 Ipsen Biopharm Limited Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
US12156872B2 (en) * 2017-05-09 2024-12-03 Tesaro, Inc. Combination therapies for treating cancer
CA3063715A1 (en) 2017-05-18 2018-11-22 Tesaro, Inc. Combination therapies for treating cancer
GB201709076D0 (en) * 2017-06-07 2017-07-19 Inst Of Cancer Research: Royal Cancer Hospital Parp inhibitors for use in methods of treating cancer
CN111372607A (zh) 2017-09-30 2020-07-03 特沙诺有限公司 用于治疗癌症的联合疗法
US11801240B2 (en) 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof
KR20200085307A (ko) * 2017-11-04 2020-07-14 아라바이브 바이올로직스, 인크. Axl 유인 수용체를 이용한 전이성 암의 치료 방법
MX2020007306A (es) 2018-01-12 2020-09-25 Prolynx Llc Tratamiento sinergico de cancer.
WO2019200382A1 (en) * 2018-04-13 2019-10-17 The Board Of Regents Of University Of Texas System Nanoparticle compositions and methods of use of parp inhibitor for treatment of cancer
AU2019275722A1 (en) * 2018-06-01 2020-11-12 Beigene, Ltd. Maintenance therapy of a PARP inhibitor in treating gastric cancer
AU2019395284B2 (en) * 2018-12-14 2025-07-17 Health Hope Pharma Hk Limited Therapeutic combinations of orally administered irinotecan and a P-gp inhibitor for the treatment of cancer
CN114053415B (zh) * 2020-07-30 2024-06-18 江苏天士力帝益药业有限公司 Tsl-1502复方药物组合
CN114053271B (zh) * 2020-07-30 2024-05-07 江苏天士力帝益药业有限公司 一种含有tsl-1502m的药物组合物及其应用
WO2022233782A1 (en) * 2021-05-03 2022-11-10 Lead Discovery Center Gmbh Composition comprising an inhibitor of mitochondrial transcription
RU2769543C2 (ru) * 2021-07-21 2022-04-01 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ оценки первичного ответа на проводимую комбинированную химиотерапию спорадического рака яичников III и IV стадий
CN114259569B (zh) * 2021-12-30 2024-02-27 中山大学附属第八医院（深圳福田） 基于伊立替康和尼拉帕利的超分子纳米药物的制备方法和应用
EP4209217A1 (en) * 2022-01-11 2023-07-12 Fundación Profesor Novoa Santos Method for the treatment of brca1/2 mutated cancer
TW202434243A (zh) 2022-11-21 2024-09-01 日商富士軟片股份有限公司 含有內含拓普替康或其鹽之脂質體組成物及ｄｎａ損傷修復抑制劑之組合醫藥
JP2025075711A (ja) * 2023-10-31 2025-05-15 国立大学法人 大分大学 Ｂｒｃａ遺伝子を含む相同組換え欠損が原因となって発症する癌の治療のための治療剤、医薬組成物、化合物、使用、治療方法、及びスクリーニング方法

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
JPH0720857B2 (ja) 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5538954A (en) 1994-06-24 1996-07-23 A/S Dumex (Dumex Ltd.) Salts of tetracyclines
US5783568A (en) 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
DE19605024A1 (de) 1996-01-31 1997-08-07 Schering Ag Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
WO1998017256A1 (en) 1996-10-22 1998-04-30 Dmitri Kirpotin Compound-loaded liposomes and methods for their preparation
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
DE69907243T2 (de) 1998-09-16 2004-02-19 Alza Corp., Mountain View In liposomen eingeschlossene topoisomerase inhibitoren
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
AU4564200A (en) 1999-04-29 2000-11-17 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
WO2001056548A2 (en) 2000-02-04 2001-08-09 Lipoxen Technologies Limited Liposomes composition produced by a dehydration-rehydration process
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
CA2408710C (en) 2000-05-15 2010-01-26 Celgene Corp. Compositions and methods for the treatment of colorectal cancer
WO2002002077A2 (en) 2000-06-30 2002-01-10 Inex Pharmaceuticals Corporation Liposomal antineoplastic drugs and uses thereof
TWI283575B (en) 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
MXPA03008864A (es) 2001-03-26 2004-12-06 Johnson & Johnson Composicion de liposoma para el suministro intracelular mejorado en un agente terapeutico.
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
WO2003030864A1 (en) 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
AU2002328945A1 (en) 2001-07-23 2003-02-24 Epidauros Biotechnologie Ag Methods for improved treatment of cancer with irinotecan based on mrp1
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
AU2003237864B2 (en) 2002-05-15 2008-12-18 California Pacific Medical Center Delivery of nucleic acid-like compounds
US20060166892A1 (en) 2002-05-31 2006-07-27 Alvarez Vernon L Treatment of cell proliferative disorders with chlorotoxin
AU2003296897A1 (en) 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
KR20160014775A (ko) 2003-05-30 2016-02-11 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
UA86063C2 (ru) 2004-05-03 2009-03-25 Хермес Біосайенсез, Інк. Липосомы для снабжения лекарств
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
ES2594621T3 (es) 2004-06-01 2016-12-21 Kabushiki Kaisha Yakult Honsha Preparación de irinotecán
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
WO2007050784A2 (en) 2005-10-25 2007-05-03 Celator Pharmaceuticals, Inc. Fixed ratio drug combination treatments for solid tumors
US20090148506A1 (en) 2005-12-22 2009-06-11 Awa Dicko Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof
JP5289060B2 (ja) 2006-01-17 2013-09-11 アボット・ラボラトリーズ Ｐａｒｐインヒビターとの組合せ療法
US20080146638A1 (en) 2006-01-17 2008-06-19 Abbott Laboratories Combination therapy with parp inhibitors
US20070219268A1 (en) 2006-03-16 2007-09-20 Bionumerik Pharmaceuticals, Inc. Anti-cancer activity augmentation compounds and formulations and methods of use thereof
PL2129396T3 (pl) 2007-02-16 2014-02-28 Merrimack Pharmaceuticals Inc Przeciwciała przeciw ERBB3 i ich zastosowania
CA2681302C (en) 2007-03-19 2013-07-23 Dhiraj Khattar Proliposomal and liposomal compositions of poorly water-soluble compounds
US20120003160A1 (en) 2007-06-29 2012-01-05 Amag Pharmaceuticals, Inc. Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session
ES2550759T3 (es) 2007-08-17 2015-11-12 Celator Pharmaceuticals, Inc. Formulaciones farmacológicas de platino mejoradas
CN101878229A (zh) 2007-09-28 2010-11-03 巴塞尔大学医院 用于治疗癌症的免疫脂质体
CA2705417A1 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
AU2008333786A1 (en) 2007-12-07 2009-06-11 Bipar Sciences, Inc. Treatment of cancer with combinations of topoisomerase inhibitors and PARP inhibitors
CA2718918A1 (en) 2008-03-25 2009-11-26 Schering Corporation Methods for treating or preventing colorectal cancer
US8067432B2 (en) 2008-03-31 2011-11-29 University Of Kentucky Research Foundation Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors
EA022201B1 (ru) 2008-04-11 2015-11-30 Мерримак Фармасьютикалз, Инк. Агент, способный связываться с опухолевой клеткой, содержащий линкер на основе hsa, и его применение
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
EA201171195A8 (ru) 2009-03-30 2014-08-29 Серулин Фарма Инк. Конъюгаты, частицы, композиции "полимер-агент" и способы их применения
JP2012525371A (ja) 2009-05-01 2012-10-22 オンコザイム・ファーマ・インコーポレイテッド 癌を治療するためのペンタミジンの組み合わせ
WO2011034954A1 (en) 2009-09-15 2011-03-24 Cerulean Pharma Inc. Treatment of cancer
SI2508170T1 (sl) 2009-12-03 2015-12-31 Jiangsu Hengrui Medicine Co., Ltd. Liposom z irinotekanom ali njegovim hidrokloridom in njun postopek priprave
JP6257324B2 (ja) 2010-06-04 2018-01-10 アブラクシス バイオサイエンス， エルエルシー 膵臓がんの処置方法
CN103153283B (zh) 2010-06-19 2017-05-17 健康科学西部大学 Peg化脂质体包封的糖肽抗生素的新制剂
JP2013531068A (ja) 2010-07-19 2013-08-01 バイパー サイエンシズ，インコーポレイティド ４−ヨード−３−ニトロベンズアミドを抗腫瘍剤と組み合わせて用いる乳癌の治療方法
KR20130048242A (ko) 2010-07-22 2013-05-09 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 항-종양 항원 항체 및 이용 방법
WO2012031293A1 (en) 2010-09-03 2012-03-08 Board Of Regents Of The University Of Nebraska Compositions and methods for the treatment of cancer
CN103327983A (zh) 2010-12-06 2013-09-25 梅里麦克制药股份有限公司 在使用包含蒽环类化疗剂的erbb2靶向免疫脂质体的治疗中防止心肌毒性的剂量和给药
EP2651447B1 (en) 2010-12-14 2018-08-29 Technical University of Denmark Entrapment of radionuclides in nanoparticle compositions
AU2012217685B2 (en) 2011-02-15 2017-05-18 Merrimack Pharmaceuticals, Inc. Compositions and methods for delivering nucleic acid to a cell
KR20140138353A (ko) 2011-04-19 2014-12-03 메리맥 파마슈티컬즈, 인크. 단일특이적 및 이중특이적 항-igf-1r 및 항 erbb3 항체
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
WO2013138371A1 (en) 2012-03-12 2013-09-19 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody
US9511155B2 (en) 2012-04-17 2016-12-06 Merrimack Pharmaceuticals, Inc. Compositions and methods for non-invasive imaging
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
HK1210913A1 (en) 2012-08-31 2016-05-13 索隆-基特林癌症研究协会 Particles, methods and uses thereof
WO2014113167A1 (en) 2012-12-14 2014-07-24 Merrimack Pharmaceuticals, Inc. Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents
US9616081B2 (en) 2013-03-27 2017-04-11 Taiho Pharmaceutical Co., Ltd. Antitumor agent including low-dose irinotecan hydrochloride hydrate
US10111871B2 (en) 2013-08-27 2018-10-30 Northeastern University Nanoparticle drug delivery system and method of treating cancer and neurotrauma
US20160303264A1 (en) 2013-10-23 2016-10-20 Merrimack Pharmaceuticals, Inc. Liposomes useful for non-invasive imaging and drug delivery
JP7113619B2 (ja) 2014-12-09 2022-08-05 イプセン バイオファーム リミティド リポソーマルイリノテカンによる乳がんの治療
WO2016168451A1 (en) 2015-04-14 2016-10-20 Merrimack Pharmaceuticals, Inc. Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
PL3337467T3 (pl) 2015-08-20 2021-06-14 Ipsen Biopharm Ltd. Terapia skojarzona z zastosowaniem liposomalnego irynotekanu i inhibitora parp do leczenia nowotworu
IL257149B2 (en) 2015-08-21 2024-11-01 Ipsen Biopharm Ltd Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
MX382522B (es) 2015-10-16 2025-03-13 Ipsen Biopharm Ltd Composiciones farmaceuticas estabilizantes de camptotecina.
US20170202840A1 (en) 2016-01-14 2017-07-20 Merrimack Pharmaceuticals, Inc. Treatment of pancreatic cancer with liposomal irinotecan
WO2017172678A1 (en) 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
US20170333421A1 (en) 2016-05-18 2017-11-23 Ipsen Biopharm Ltd. Population Pharmacokinetics of Liposomal Irinotecan
MA45046A (fr) 2016-05-18 2019-03-27 Ipsen Biopharm Ltd Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellules
EP3535026A1 (en) 2016-11-02 2019-09-11 Ipsen Biopharm Limited Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)

Also Published As

Publication number Publication date
HK1257249A1 (en) 2019-10-18
EP3337467A1 (en) 2018-06-27
US20200268742A1 (en) 2020-08-27
JP7042739B2 (ja) 2022-03-28
US9895365B2 (en) 2018-02-20
KR20180037210A (ko) 2018-04-11
EP3337467B1 (en) 2020-12-09
CA2992789A1 (en) 2017-02-23
US20180117034A1 (en) 2018-05-03
MX2018001659A (es) 2018-05-28
SI3337467T1 (sl) 2021-03-31
CN108348480A (zh) 2018-07-31
RU2760185C2 (ru) 2021-11-22
US20170049767A1 (en) 2017-02-23
WO2017031442A1 (en) 2017-02-23
US10478428B2 (en) 2019-11-19
AU2016309002A1 (en) 2018-02-08
RU2018105655A3 (es) 2020-02-21
TW201713312A (zh) 2017-04-16
ES2848118T3 (es) 2021-08-05
WO2017031445A1 (en) 2017-02-23
HK1257216A1 (zh) 2019-10-18
PL3337467T3 (pl) 2021-06-14
RU2018105655A (ru) 2019-09-23
US20230074866A1 (en) 2023-03-09
IL257147B (en) 2021-07-29
AU2016309002B2 (en) 2021-07-29
US11844795B2 (en) 2023-12-19
SG10201913073YA (en) 2020-03-30
JP2018528184A (ja) 2018-09-27
TWI724018B (zh) 2021-04-11
PT3337467T (pt) 2021-01-25
IL257147A (en) 2018-03-29

Similar Documents

Publication Publication Date Title
MX381475B (es) Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer.
WO2016025635A3 (en) Combination therapy for treating cancer
PH12019500892A1 (en) Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
MX2016007351A (es) Terapia de combinacion para tratar cancer.
MX391720B (es) Terapia combinada para tratar cáncer.
BR112018013731A2 (pt) combinações anti-egfr para o tratamento de tumores
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
WO2017053889A3 (en) Flt3 directed car cells for immunotherapy
WO2016043874A3 (en) Combination therapy for treating cancer
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
EA201591924A1 (ru) Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
MX2019003134A (es) Terapia de combinacion.
MX376193B (es) Compuestos para tratar el cancer cerebral.
MX386415B (es) Uso de (s)-n-(5-((r)-2-(2,5-difluorofenil) pirrolidin-1-il)- pirazolo [1,5-a] pirimidin-3-il) -3-hidroxipirrolidina-1- carboxamida para tratar cánceres pediátricos.
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
PH12018502422A1 (en) Nanoliposomal irinotecan for use in treating small cell lung cancer
MX2020001727A (es) Terapia de combinacion.
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
HK1250626A1 (zh) 借助塞里班土单抗的组合治疗
WO2018102261A3 (en) Boronic derivatives hydroxamates as anticancer agents
PH12018500450A1 (en) Immunity enhancing agent for cancer by allergin-1 antagonist